Literature DB >> 1483484

Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis.

F R Ibarra1, C Afione, D Garzon, M Barontini, J C Santos, E Arrizurieta.   

Abstract

The acute effects of captopril in cirrhosis are well known but there are few descriptions of the pattern of response to chronic administration of captopril in this disease. Nine nonuraemic cirrhotic patients with ascites and portal hypertension were studied after 1 week on fixed sodium and water intake (balance diet) and following acute and chronic treatment with captopril (three doses of 25 mg every 30 min and 75 mg.day-1 for three weeks, respectively). Whilst on the balance diet, 7/9 patients were unable to excrete the amount of sodium ingested. After the acute administration of captopril, a significant reduction was seen in arterial blood pressure (86.9 vs 77 mm Hg), with no change in the intra-hepatic pressures (free suprahepatic pressure, FSHP: 15.0 vs 12.1 mm Hg and wedged suprahepatic pressure, WSHP: 22.9 vs 20.7 mm Hg). After chronic captopril treatment, a drop was observed in portal pressure (FSHP: 9.4 mm Hg and WSHP 18.8 mm Hg, NS) and the arterial pressure returned to its basal level. The plasma aldosterone concentration decreased, whilst noradrenaline and dopamine increased significantly, the latter more than the former, leading to a reduction in the noradrenaline/dopamine ratio (14.5 vs 5.0). Seven out of nine patients showed enhanced natriuresis and the remaining two, who previously had had a positive sodium balance failed to do so. These haemodynamic, hormonal and renal changes were interpreted as evidence of blockade of angiotensin II generation by captopril, and also as a homoeostatic response by the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483484     DOI: 10.1007/bf02285088

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Captopril, kallikrein, and hypertension.

Authors:  M Marin-Grez; G Bönner; F Gross
Journal:  Lancet       Date:  1980-05-10       Impact factor: 79.321

Review 2.  The renin-angiotensin systems.

Authors:  R N Re
Journal:  Med Clin North Am       Date:  1987-09       Impact factor: 5.456

3.  Renal tubular actions of antihypertensive agents.

Authors:  W N Suki; D Rouse
Journal:  Kidney Int Suppl       Date:  1988-09       Impact factor: 10.545

Review 4.  Disturbed volume homeostasis in patients with cirrhosis of the liver.

Authors:  O S Better; R W Schrier
Journal:  Kidney Int       Date:  1983-02       Impact factor: 10.612

5.  Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients.

Authors:  M H Weinberger
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

Review 6.  Renal adaptation to sodium deprivation. Effect of captopril in the rat.

Authors:  A Mimran; B Jover; D Casellas
Journal:  Am J Med       Date:  1984-05-31       Impact factor: 4.965

7.  Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics.

Authors:  R M Pérez-Ayuso; V Arroyo; J Camps; A Rimola; J Costa; J Gaya; F Rivera; J Rodés
Journal:  Hepatology       Date:  1984 Mar-Apr       Impact factor: 17.425

8.  Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

Authors:  V Arroyo; J Bosch; M Mauri; F Ribera; F Navarro-López; J Rodés
Journal:  Eur J Clin Invest       Date:  1981-06       Impact factor: 4.686

9.  Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites.

Authors:  V Arroyo; J Bosch; J Gaya-Beltrán; D Kravetz; L Estrada; F Rivera; J Rodés
Journal:  Ann Intern Med       Date:  1981-02       Impact factor: 25.391

10.  The significance of duration of salt loading on cardiovascular response and urinary excretion of catecholamine in rats.

Authors:  M Yoshimura; H Yamazaki; R Takashina; S Kambara; I Iyoda; S Sasaki; H Takahashi; K Takeda; H Ijichi
Journal:  Endocrinol Jpn       Date:  1986-04
View more
  3 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

2.  Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.

Authors:  Wilma Debernardi-Venon; Claudio Barletti; Carlo Alessandria; Alfredo Marzano; M Baronio; Luca Todros; Giorgio Saracco; Alessandro Repici; Mario Rizzetto
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

3.  Quantitative modeling of the physiology of ascites in portal hypertension.

Authors:  David G Levitt; Michael D Levitt
Journal:  BMC Gastroenterol       Date:  2012-03-27       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.